CN1676520A - Kuh-seng flavone extract and preparation and use thereof - Google Patents

Kuh-seng flavone extract and preparation and use thereof Download PDF

Info

Publication number
CN1676520A
CN1676520A CNA200410030937XA CN200410030937A CN1676520A CN 1676520 A CN1676520 A CN 1676520A CN A200410030937X A CNA200410030937X A CN A200410030937XA CN 200410030937 A CN200410030937 A CN 200410030937A CN 1676520 A CN1676520 A CN 1676520A
Authority
CN
China
Prior art keywords
kuh
kurarinone
seng
total flavone
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA200410030937XA
Other languages
Chinese (zh)
Inventor
严孝强
崔玉敏
王滔
马志明
潘柯
张维权
黄伟晖
洪建荣
段继峰
蔡宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hutchison Whampoa Ltd
Original Assignee
Hutchison Whampoa Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hutchison Whampoa Ltd filed Critical Hutchison Whampoa Ltd
Priority to CNA200410030937XA priority Critical patent/CN1676520A/en
Priority to PCT/CN2005/000436 priority patent/WO2005095375A1/en
Publication of CN1676520A publication Critical patent/CN1676520A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

This invention relates to kuh-seng total ketone extractor that has TNF A and IL-I beta restrain effect, and its making method and the medicate combinations.

Description

A kind of kuh-seng total flavone extract and its production and use
Technical field
The present invention relates to a kind of plant milk extract, especially relate to the inhibiting kuh-seng total flavone extract of a kind of TNF of having α and IL-1 β, its preparation method and contain the pharmaceutical composition of this extract and the pharmaceutical applications of this extract.
Background technology
To be body cause the reaction based on defence that damage took place that inflammatory factor causes to various to inflammation, and the topical manifestations of inflammation is red, and is swollen, heat, pain and dysfunction.Comparatively obvious when these show acute body surface inflammation, how not obvious the inflammation and the chronic inflammatory diseases of internal organ be then.It is local that inflammation not only shows, and often cause systemic reaction.Common systemic reaction has heating, and the white corpuscle number in the blood increases and the heart, liver, and sex change in various degree can appear in parenchymatous organs such as kidney, pathologies such as necrosis.
By pathological classification, inflammation can be divided into alterative inflammation, serous inflammation, fibrinous inflammation, suppurative inflammation, hemorrhagic inflammation, catarrhal inflammation, productive inflammation and chronic granuloma inflammation.
TNF α is a kind of precursor inflammatory cytokine, is mainly produced by monocyte and scavenger cell, participates in the process of many inflammatory reactions.Intracellular toxin (LPS) is the inductor of TNF α.Discover that TNF α has the various biological activity: 1) kill and wound or suppress tumour cell; 2) phagocytic activity of raising neutrophil leucocyte increases superoxide anion and produces, and participates in inflammatory reaction; 3) anti-infective etc.According to the literature, the TNF alpha inhibitor can be used for rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, SpA, inflammatory bowel, in heart failure, diabetes, systemic lupus erythematous, scleroderma, sarcoidosis, dermatomyositis, psoriatic, multiple myeloma, myelodysplastic syndrome, acute marrow type leukemia, Parkinson's disease, acquired immune deficiency syndrome and dementia and syndrome, presenile dementia, dysthymia disorders, Sepsis, pyoderma gangraenosum, septicemia, septic shock, behcets disease, graft versus host disease (GVH disease), uveitis, Wegener ' s granuloma, the Xiu Gelianshi xerosis, chronic obstructive pulmonary disease, asthma, acute pancreatitis, periodontopathy, emaciation, cancer, central nervous system injury, respiratory virus infection, the treatment of various disease conditions such as obesity (1-25)(1.Ogata H, Hibi T.et al Curr Pharm Des.2003; 9 (14): 1107-13.2.Moller DR.et alJ Intern Med.2003 Jan; 253 (1): 31-40.3.Taylor PC.Et al Curr Pharm Des.2003; 9 (14): 1095-106.4.Wilkinson N et al Arch Dis Child.2003 Mar; 88 (3): 186-91.5.Nishimura F et al J Periodontol.2003 Jan; 74 (1): 97-102.6.Weinberg J M et alCutis.2003 Jan; 71 (1): 41-5.7.Burnham E et al Crit Care Med.2001 Mar; 29 (3): 690-1.8.Sack M.et al Pharmacol Ther.2002 Apr-May; 94 (1-2): 123-35.9.BarnesPJ.Et al Annu Rev Pharmacol Toxicol.2002; 42:81-98.10.Mageed RA et al Lupus.2002; 11 (12): 850-5.11.Tsimberidou AM et al Expert Rev Anticancer Ther.2002Jun; 2 (3): 277-86.12.Muller T.et al Curr Opin Investig Drugs.2002 Dec; 3 (12): 1763-7.13.Calandra T et al Curr Clin Top Infect Dis.2002; 22:1-23.14.Girolomoni G et al Curr Opin Investig Drugs.2002 Nov; 3 (11): 1590-5.15.Tutuncu Z et al Clin Exp Rheumatol.2002 Nov-Dec; 20 (6 Suppl 28): S146-51.16.Braun J et al Best Pract Res Clin Rheumatol.2002 Sep; 16 (4): 631-51.17.BarnesPJ.Et al Novartis Found Symp.2001; 234:255-67; Discussion 267-72.18.Brady M, et al Baillieres Best Pract Res Clin Gastroenterol.1999 Jul; 13 (2): 265-89.19.Goldring MB.et al Expert Opin Biol Ther.2001 Sep; 1 (5): 817-29.20.Mariette X.Rev Prat.2003 Mar 1; 53 (5): 507-11.21.Sharma R et al Int J Cardiol.2002 Sep; 85 (1): 161-71.22.Wang CX et al Prog Neurobiol.2002 Jun; 67 (2): 161-72.23.VanReeth K et al Vet Immunol Immunopathol.2002 Sep 10; 87 (3-4): 161-8.24.Leonard BE et al Int J Dev Neurosci.2001 Jun; 19 (3): 305-12.25.Hays SJ et alCurr Pharm Des.1998 Aug; 4 (4): 335-48.).Report TNF α such as Marc Feldmann have been used as the medicine target of screening rheumatoid arthritis and other Parmaceutical for treating disease of autoimmunization system things (26)(26.MarcFeldmann et al.Nature Medicine.2003 Oct; 9 (10): 1245-50).
IL-1 β is a kind of cytokine that is produced by mononuclear macrophage, dendritic cell, fibroblast etc.It can stimulate propagation and differentiation, the hemopoietic of T cell and B cell and participate in inflammatory reaction.According to the literature, the IL-1 beta inhibitor can be used for the treatment of various disease conditions such as rheumatoid arthritis, septicemia, periodontopathy, heart failure, dermatomyositis, acute pancreatitis, chronic obstructive pulmonary disease, presenile dementia, osteoarthritis, infectation of bacteria, multiple myeloma, myelodysplastic syndrome, uveitis, central nervous system injury, respiratory virus infection, asthma, dysthymia disorders, scleroderma (27-46)(27.Taylor PC.et al Curr Pharm Des.2003; 9 (14): 1095-106.28.Dellinger RP et al Clin Infect Dis.2003 May 15; 36 (10): 1259-65.29.Takashiba S et al J Periodontol.2003 Jan; 74 (1): 103-10.30.Diwan A, et al Curr Mol Med.2003 Mar; 3 (2): 161-82.31.Lundberg IE, et al Rheum Dis Clin North Am.2002 Nov; 28 (4): 799-822.32.Makhija R, et al JHepatobiliary Pancreat Surg.2002; 9 (4): 401-10.33.Chung KF.Et al Eur Respir JSuppl.2001 Dec; 34:50s-59s.34.Hallegua DS, et al Ann Rheum Dis.2002 Nov; 61 (11): 960-7.35.Goldring MB.Et al Expert Opin Biol Ther.2001 Sep; 1 (5): 817-29.36.Mrak RE, Griffin WS.Et al Neurobiol Aging.2001 Nov-Dec; 22 (6): 903-8.37.Brady M, et al Baillieres Best Pract Res Clin Gastroenterol.1999 Jul; 13 (2): 265-89.38.Van der Meer JW, et al Ann N Y Acad Sci.1998 Sep 29; 856:243-51.39.Rameshwar P et al Acta Haematol.2003; 109 (1): 1-10.40.deKozak Y et al Int Rev Immunol.2002 Mar-Jun; 21 (2-3): 231-53.41.Wang CX et alProg Neurobiol.2002 Jun; 67 (2): 161-72.42.Van Reeth K et al Vet ImmunolImmunopathol.2002 S ep 10; 87 (3-4): 161-8.43.Stirling R G et al Br M ed B ull.2000; 56 (4): 1037-53.44.Leonard BE et al Int J Dev Neurosci.2001 Jun; 19 (3): 305-12.45.Allan SM et al Ann N Y Acad Sci.2000; 917:84-93.46.Cafagna D et alMinerva Med.1998 May; 89 (5): 153-61.).
Traditional Chinese medicine kuh-seng (Sophora flavescens Ait) is a cassia leguminous plant, its bitter cold in nature, the effect of clearing heat and detoxicating, the tear only of making eye bright, wind dispelling insecticide, five viscera settling are arranged, turning round sedate.Therefrom isolated main chemical compositions can be divided into two big class, i.e. Radix Sophorae Flavescentis alkaloid and kuh-seng flavones.Someone has isolated 23 kinds of alkaloids and 32 kinds of flavones and isoflavonoid from radix sophorae, stem, leaf with spending (47)(47. seedlings are anti-upright, Zhang Jianzhong etc., research and development of natural products, 2000,13 (2): 69～73).
The main plant source of kurarinone (Kurarinone) is the bark of ash (Gentiana macrophylla Pall) of kuh-seng of pulse family (Sophora flavescensAit) and Gentianaceae, and its chemical structural formula is:
Molecular formula C 26H 30O 6, molecular weight 438.52,121～123 ℃ of fusing points
2 '-methoxyl group-kurarinone (2 '-methoxy-Kurarinone) has another name called Vexibidin (Isokurarinone), is yellow crystals, and its chemical structural formula is:
Figure A20041003093700052
Molecular formula C 27H 32O 6, molecular weight 438, fusing point 102-104 ℃
Chinese scholartree flavanone G (Sophoraflavanone G) has another name called Vexibinol (Norkurarinone), is colourless needle (benzene) that its chemical structural formula is:
Molecular formula C 25H 28O 6, molecular weight 424.49, fusing point 173-175 ℃
Do not see that existing document can suppress the report of TNF α and IL-1 β expression about kurarinone, 2-methoxyl group-kurarinone and Chinese scholartree flavanone.
Summary of the invention
The present invention relates to the inhibiting kuh-seng total flavone extract of a kind of TNF of having α and IL-1 β.This extract comprises following weight ratio composition: kurarinone 20～40%, 2-methoxyl group-kurarinone 1～5% and Chinese scholartree flavanone 1～10%.Particularly, this extract can contain 30% kurarinone, 2%2 '-methoxyl group-kurarinone and 5% Chinese scholartree flavanone.
The invention still further relates to a kind of pharmaceutical composition that comprises above-mentioned kuh-seng total flavone extract.
The invention still further relates to above-mentioned kuh-seng total flavone preparation method of extract.
The invention still further relates to the purposes of above-mentioned kuh-seng total flavone extract in preparation TNF alpha inhibitor and IL-1 beta inhibitor.
Described " TNF alpha inhibitor " can be used for treating following illness, includes but not limited to: SpA, inflammatory bowel, in heart failure, diabetes, systemic lupus erythematous, scleroderma, sarcoidosis, dermatomyositis, psoriatic, multiple myeloma, myelodysplastic syndrome, acute marrow type leukemia, Parkinson's disease, presenile dementia, dysthymia disorders, acquired immune deficiency syndrome and dementia and syndrome, Sepsis, pyoderma gangraenosum, septicemia, septic shock, behcets disease, graft versus host disease (GVH disease), uveitis, Wegener ' s granuloma, the Xiu Gelianshi xerosis, chronic obstructive pulmonary disease, asthma, acute pancreatitis, periodontopathy, emaciation, central nervous system injury or obesity.
Described " IL-1 beta inhibitor " can be used for treating following illness, includes but not limited to: septicemia, periodontopathy, heart failure, dermatomyositis, acute pancreatitis, chronic obstructive pulmonary disease, presenile dementia, osteoarthritis, infectation of bacteria, myelodysplastic syndrome, uveitis, central nervous system injury, asthma, dysthymia disorders or scleroderma.
The details of all respects of the present invention will be able to detailed description in chapters and sections subsequently.By hereinafter and the description of claim, other characteristics of the present invention, purpose and advantage will be more obvious.
Appearance of the present invention part is based on so unexpected discovery: kurarinone, 2 '-methoxyl group-kurarinone and Chinese scholartree flavanone G are present in specific ratio and have TNF α and IL-1 β suppresses in the active kuh-seng total flavone extract.Therefore, this kuh-seng total flavone extract can be used for preparing TNF alpha inhibitor and IL-1 beta inhibitor.
Described " TNF-alpha inhibitor " can be used for treating following illness, includes but not limited to: SpA (spondyloarthropathies), inflammatory bowel (inflammatory bowel disease), (heart failure) in heart failure, diabetes (diabetes mellitus), systemic lupus erythematous (systemic lupuservthematosus), scleroderma (scleroderma), sarcoidosis (sarcoidosis), dermatomyositis (polymyositis/dermatomyositis), psoriatic (psoriasis), myelodysplastic syndrome (myelodysplastic syndrome), acute marrow type leukemia (acute myelogenous leukemia), Parkinson's disease (Parkinson ' s disease), acquired immune deficiency syndrome and dementia and syndrome (AIDS dementia complex), presenile dementia (Alzheimer ' s disease), dysthymia disorders (depression), Sepsis (sepsis), pyoderma gangraenosum (pyoderma gangrenosum), septicemia (hematosepsis), septic shock (septic shock), behcets disease (Behcet ' s syndrome), graft versus host disease (GVH disease) (graft-versus-host disease), uveitis (uveitis), Wegener ' s granuloma (Wegener ' sgranulomatosis), Xiu Gelianshi xerosis (Sjogren ' s syndrome), chronic obstructive pulmonary disease (chronic obstructive pulmonary disease), asthma (asthma), acute pancreatitis (acutepancreatitis), periodontopathy (Periodontal disease), emaciation (cachexia), central nervous system injury (central nervous system injury), fat (obesity) etc.
Described " IL-1 beta inhibitor " can be used for treating following illness, includes but not limited to: septicemia (hematosepsis), periodontopathy (Periodontal disease), (heart failure) in heart failure, dermatomyositis (polymyositis/dermatomyositis), acute pancreatitis (acute pancreatitis), chronic obstructive pulmonary disease (chronic obstructive pulmonary disease), presenile dementia (Alzheimer ' sdisease), osteoarthritis (osteoarthritis), infectation of bacteria (Bacterial infections), myelodysplastic syndrome (myelodysplastic syndrome) uveitis (uveitis), central nervous system injury (central nervous system injury), asthma (asthma), dysthymia disorders (depression), scleroderma (scleroderma) etc.
Term " backbone joint disease " (spondyloarthropathies) is meant one group of multisystem diseases associated with inflammation with inner link.Therefore the Rheumatoid factors, polyclonal (rheumatoid factor) in its blood of class disease patient is negative, so be called " seronegative spondyloanthropathy (seronegative spondyloarthropathies) again.This disease can be involved backbone, periphery joint, joint surrounding structure or three and all be involved, and with showing outside the various distinctive joints, as acute and chronic stomach and intestine or inflammation of genito-urinary system disease (can be infection sometimes), preocular inflammation, psoriatic skin, nail infringement etc.This group disease mainly comprises: ankylosing spondylitis (Ankylosing spondylitis), auspicious special syndrome (Reiter ' s syndrome), psoriasis arthropathica (Psoriatic arthropathy), inflammatory bowel characteristic of disease sacroiliitis (Inflammatory bowel diseasearthritis), undifferentiated type SpA (Undifferentiated spondyloarthropathy) etc.
Term " inflammatory bowel " (inflammatory bowel disease) is the general designation of crohn (Crohn ' s disease) and two kinds of non-specific enteritis of ulcerative colitis (ulcerative colitis).
(chronic obstructive pulmonary disease COPD) is meant chronic bronchitis and/or the pulmonary emphysema (American Thoracic Society (ATS) and the definition of respiratory system association of Chinese Medical Association) with airflow obstruction feature to term " chronic obstructive pulmonary disease ".Some bronchial asthma develops into the non-reversibility airflow obstruction in disease process, when bronchial asthma and chronic bronchitis and/or the overlapping existence of pulmonary emphysema or when being difficult to differentiate, also can list the COPD scope in.The principal character of COPD is the chronic progressive external airflow obstruction.
Comprise following weight ratio composition in the kuh-seng total flavone extract of the present invention: kurarinone 20～60%, 2 '-methoxyl group-kurarinone 1～5% and Chinese scholartree flavanone G1～12%; Preferably, this extract contains kurarinone 35～45%, 2 '-methoxyl group-kurarinone 2～4% and Chinese scholartree flavanone G5～8%; Particularly, this extract can contain kurarinone 45%, 2-methoxyl group-kurarinone 2% and Chinese scholartree flavanone 6%.This extract can be by method of the present invention preparation, promptly kuh-seng through organic solvent extraction such as ethanol, ethyl acetate, concentrate, the gained crude extract is dissolved in 5%～50%C1～C4 alcohol solution, uses organic solvent extraction again, merges organic phase, concentrate product.Described C1～C4 alcohol solution can be methyl alcohol, ethanol, propyl alcohol, Virahol or the butanols aqueous solution; The concentration of described C1～C4 alcohol solution is 5%～50%, and is preferred 20～40%, most preferably 30%; Described organic solvent is selected from ethyl acetate, chloroform, acetone, ether or its mixture.
Can add pharmaceutically acceptable carrier in the kuh-seng total flavone extract of the present invention to promote its administration.Preferable, pharmaceutical composition of the present invention contains extract or its active ingredient of 0.1-99.9% weight ratio." pharmaceutically acceptable carrier " can not destroy the pharmaceutical active of kuh-seng total flavone extract of the present invention or its active ingredient, its effective level simultaneously, and promptly can playing pharmaceutical carrier, to make the consumption of time spent nontoxic to human body.
" pharmaceutically acceptable carrier " includes but not limited to: ion-exchange material, aluminum oxide, aluminum stearate, Yelkin TTS, self-emulsifying drug delivery system (SEDDS) is as d-alpha-vitamin E polyethylene glycol 1000 succinates, the surfactant that pharmaceutical preparations such as tween (Tweens) or other similar polymerisation mediums are used, serum protein such as human serum albumin, buffer substance such as phosphoric acid salt, Padil, Sorbic Acid, potassium sorbate, saturated vegetable fatty acid partial glycerol ester mixture, water, salt, ionogen such as vitriol protamine, phosphoric acid hydrogen two is received, potassium hydrogen phosphate, sodium-chlor, zinc salt, silica gel, Magnesium Silicate q-agent etc.Povidone, cellulosic material, polyvinyl alcohol, Xylo-Mucine, polypropylene acid esters, ethene-polyoxyethylene-block polymer and wool grease, cyclodextrin such as α-, β-and γ-Huan Hujing or its all can be used for promoting the useful for drug delivery of kuh-seng total flavone extract of the present invention or its active ingredient through hydroxyalkyl cyclodextrin such as the derivative of chemically modified such as 2-and 3-hydroxypropyl-beta-cyclodextrin or other soluble derivatives etc.
Other pharmaceutically acceptable auxiliaries such as weighting agent (as lactose hydrous, starch, lactose bead and glucose), tackiness agent (as Microcrystalline Cellulose), disintegrating agent (as crosslinked carboxymethyl fecula sodium, croscarmellose sodium, low-substituted hydroxypropyl cellulose and cross-linked pvp), lubricant (as magnesium stearate), absorption enhancer, flavouring agent, sweeting agent, thinner, vehicle, wetting agent, solvent, solubilizing agent and tinting material etc. also can add in the pharmaceutical composition of the present invention.
Above-mentioned kuh-seng total flavone extract, its active ingredient and pharmaceutical composition can pass through enteron aisle or parenteral route administration.The enterally administering preparation comprises pill, granule, capsule, suspension or solution.Non-intestinal drug delivery agent comprises injection, creme, paste, patch or sprays.That the parenterai administration approach comprises is subcutaneous, in the intracutaneous, artery, vein, muscle, joint, synovia, breastbone, sheath, intralesional, intracranial injection or instillation.Other route of administration can comprise part, rectum, intranasal, through cheek, vagina, hypogloeeis, mucous membrane, tracheae or urethra.Kuh-seng total flavone extract, its active ingredient and pharmaceutical composition can also suck or implant by aerosol to be accumulated or mode administration such as acupuncture.
The oral preparations of kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition includes but not limited to capsule, tablet, emulsion, water suspending agent, colloidal solution, solution, microcapsule, pill, lozenge, granule, pulvis.The pharmaceutically acceptable carrier that is usually used in tablet comprises lactose and W-Gum.Usually also can add lubricants such as Magnesium Stearate.The pharmaceutically acceptable carrier that is usually used in capsule comprises lactose and dried corn starch.When making oral water suspending agent and/or emulsion, kuh-seng total flavone extract of the present invention or its active ingredient can suspend or be dissolved in the oil phase and with emulsifying agent or suspension agent and combine.If desired, also can add some sweeting agents and/or flavouring agent and/or toner.
Kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition can be made into aseptic injection, as aseptic water or oil phase suspension.This suspension can promptly use suitable dispersion agent or wetting agent (as Tween 80) and suspension agent etc. to make by the ordinary method of this area.But it can also be at the nontoxic thinner of enteron aisle external administration or the aqueous solution or the suspension in the solvent, as the solution in 1,3 butylene glycol.Relevant available support or solvent comprise N.F,USP MANNITOL, water, ringer's solution, isotonic sodium chloride etc.In addition, aseptic fixed oil often is used as the media of solvent or suspension agent, thereby comprises that the multiple soft fixed oil (bland fixed oil) of synthetic glycerine monoesters or triglyceride all is suitable for.Lipid acid can be used for preparing described injection as octadecenic acid and glyceride derivative thereof (as sweet oil or Viscotrol C, particularly its polyoxyethylene radical derivative) etc.Described oil solution or suspension also can comprise a kind of alcohol dilution agent of long-chain or dispersion agent or carboxymethyl cellulose or similar other dispersion agents, and this type of material is usually used in preparing pharmaceutical acceptable emulsion and/or suspension agent.Tensio-active agent that some other preparation is commonly used such as Tweens or Spans and/or other similar emulsifying agents or bioavailability promotor etc. can be used for preparing this preparation too.
Kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition can be made into suppository and pass through rectal administration, method is that kuh-seng total flavone extract or its active ingredient are mixed with the non-irritating excipient that suits, the latter is liquid under rectal temperature for solid at room temperature, thereby this suppository can melt in rectum and discharges active ingredient.This type of vehicle includes but not limited to: theobroma oil, beeswax and polyethylene.The local administration preparation (as ointment) of kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition can be directly used in the affected part.This type of topical formulations contains active ingredient and pharmaceutically acceptable carrier, and the latter includes but not limited to mineral oil, liquid petroleum, white oil, propylene glycol, polyoxyethylene or the polyoxy third desaturation compound, emulsification is cured or water.In addition, pharmaceutical composition of the present invention also can be made into lotion or finish.The carrier that is suitable for includes but not limited to: mineral oil, sorbic alcohol monostearate, polysorbate60, spermaceti ester, cetyl alcohol, 2-Stearyl alcohol, phenmethyl ethanol or water.Kuh-seng total flavone extract of the present invention or its active ingredient also can be made into enema etc. and are used for the rectum topical.The topical transdermal patch is also within protection scope of the present invention.But kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition be intranasal spraying or inhalation also, promptly, use phenmethyl ethanol or other sanitass, absorption enhancer, fluorocarbon and/or other solubilizing agent or dispersion agent to make salts solution by the ordinary method of this area.
Kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition also can pass through drug delivery implant.Adopt the drug delivery implant mode can reach in the administration subject and continue, regularly discharge the effect of kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition.In addition, drug delivery implant can also be at local organization and organ site-specific delivery of drugs (Negrin et al., Biomaterials 22 (6): 563,2001) regularly release tech also can be used in the administration of kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition, as delayed release capsule, slow release method and the preparation technique for packing (as polymer and liposome) etc. based on the polymer technology.
Patch comprises within the scope of the present invention equally.It comprises basic unit's (as polymer, cloth, yarn and bandage) and pharmaceutical composition of the present invention.One side of basic unit can be provided with a protective layer to prevent the outflow of active ingredient.Described patch also can contain a tackiness agent that is used for fixing, and the latter can be a kind of natural or synthetic material, can temporarily adhere on the skin when it contacts with the administration subject's skin.Tackiness agent can be a waterproof.
When kuh-seng total flavone extract of the present invention, its active ingredient, pharmaceutical composition and preparation can mix with one or more additional medicines or prophylactic agent.Additional medicaments can be used as independently formulation and the administration respectively of kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition.Additional medicaments also can with kuh-seng total flavone extract of the present invention, its active ingredient and pharmaceutical composition together with single formulation administration.
For the ease of understanding the present invention, the spy enumerates following examples.Its effect should be understood that it is to annotation of the present invention but not to the restriction of any way of the present invention.Above listed each reference all is incorporated herein by reference with a full piece of writing.
Description of drawings
The restraining effect that Fig. 1 kurarinone (0912), kuh-seng total flavone extract are expressed LPS inductive TNFa;
The restraining effect that Fig. 2 kurarinone (0912), kuh-seng total flavone extract are expressed LPS inductive IL-1 β;
Fig. 3 kuh-seng total flavone extractive HPLC color atlas;
Embodiment
The invention will be further described below in conjunction with specific embodiment.But and do not mean that the present invention only limits to this.
Embodiment 1 usefulness sour water and ethyl acetate prepare the kuh-seng total flavone extract
The dried medicinal materials of kuh-seng of 500 grams merge with 9000 milliliter 95% ethanol room temperature lixiviate 3 times, extracting solution, through the vacuum concentration evaporate to dryness, crude extract 195 restrains.Extract distributes three times through 30% ethanol water and ethyl acetate (1: 1), and combined ethyl acetate solution, concentrated evaporate to dryness get 88.7 gram kuh-seng total flavones (yield 45.5%).
The separation and the evaluation of three kinds of compositions of embodiment 2 kuh-seng flavones
The separation of kurarinone and evaluation
Separate: the dried medicinal materials of kuh-seng of 500 grams are with 3000 milliliter 95% ethanol room temperature lixiviate 3 times, and extracting solution merges, through the vacuum concentration evaporate to dryness, crude extract 65 restrains.Extract distributes three times through 6% methanol-water and chloroform, and combined chloroform solution, concentrated evaporate to dryness get 30 gram medicinal extract.Medicinal extract is eluent through the LH-20 column chromatography with methyl alcohol, gets the crude products of 10 grams.Crude product is used silica gel column chromatography successively, and eluent acetone/sherwood oil=1: 2, and reversed material (RP-18) column chromatography are so that methanol=wash-out got 2 gram kurarinones (yield 0.4%) in 65: 35.
Identify:
1H?NMR(DMSO-d6，400MHz)：10.2(2’-OH)，9.4(4’-OH)，9.2(7-OH)，7.4(1H，d，J＝8.4Hz，H-6’)，6.32(1H，d，J＝2.28Hz，H-3’)，6.25(1H，dd，J＝8.2，2.4Hz，H-5’)，6.12(1H，s，H-6)，5.4(1H，dd，J＝2.6，13.1Hz，H-2)，4.9(1H，t，J＝1.4Hz，H-4”)，4.55(1H，brs，H-9”a)，4.47(1H，brs，H-9”b)，3.7(3H，s)，2.8(1H，dd，J＝13.1，16.3Hz，H-3a)，2.4(3H，m)，1.9(2H，m)，1.6(3H，s)，1.57(3H，s)，1.42(3H，s).
13C?NMR(DMSO-d6，75MHz)：188.5，162.1，161.7，159.2，157.7，154.9，147.6，130.3，127.0，123.1，116.1，110.5，106.7，106.0，104.1，102.1，92.3，73.4，55.2，46.3，44.3，30.7，26.9，25.5，18.6，17.6。
ESIMS(m/z)：439。
The separation of 2 '-methoxyl group kurarinone and evaluation
Separate: the dried medicinal materials of kuh-seng of 500 grams are with 3000 milliliter 95% ethanol room temperature lixiviate 3 times, and extracting solution merges, through the vacuum concentration evaporate to dryness, crude extract 65 restrains.Extract distributes three times through 40% propyl alcohol water and ether, merges diethyl ether solution, and concentrated evaporate to dryness gets 30 gram medicinal extract.12 gram medicinal extract are eluent through the LH-20 column chromatography with methyl alcohol, get 50 milligrams crude product.Crude product is used silica gel column chromatography successively, and eluent acetone/sherwood oil=1: 3, and reversed material (RP-18) column chromatography are so that methanol=wash-out got 20mg 2 '-methoxyl group kurarinone (yield 0.01%) in 75: 25, was yellow crystals, mp 102-104 ℃.
Identify:
1H?NMR(CDCl3，400MHz)：7.4(1H，d，J＝8.2Hz，H-6’)，6.48(1H，dd，J＝8.21，2.34Hz，H-5’)，6.44(1H，d，J＝2.35Hz，H-3’)，6.08(1H，s，H-6)，5.62(1H，m，H-2)，5.0(1H，m)，4.72(1H，brs)，4.66(1H，brs)，3.8(3H，s)，3.76(3H，s)，2.84(1H，m，H-3a)，2.4(3H，m)，1.67(3H，s)，1.63(3H，s)，1.6(2H，m)，1.52(3H，s)。
ESIMS(m/z)：451(M-1)。
UV(MeOH)λ max(logε)286(4.3)nm，
IR(KBr)v? max?3291，2955，2920，1650，1590，1500，1465，1410，1280cm -1。
Separation and the evaluation of Chinese scholartree flavanone G
Separate: the dried medicinal materials of kuh-seng of 500 grams are with 3000 milliliter 95% ethanol room temperature lixiviate 3 times, and extracting solution merges, through the vacuum concentration evaporate to dryness, crude extract 65 restrains.Extract distributes three times through 25% isopropanol water and ethyl acetate, and combined ethyl acetate solution, concentrated evaporate to dryness get 30 gram medicinal extract.Medicinal extract is eluent through the LH-20 column chromatography with methyl alcohol, gets the total flavoness of 15 grams.Crude product is with using silica gel column chromatography successively, and eluent acetone/sherwood oil=1: 3 obtains Norkurarinone crude product 500mg, and then reversed material (RP-18) column chromatography gets the Chinese scholartree flavanone G (yield 0.06%) of 300mg with methanol=70: 30 wash-outs.
Identify:
1H?NMR(DMSO-d6，400MHz)：12.1(s，5-OH)，9.6(4’-OH)，9.4(7-OH)，7.22(1H，d，J＝8.4Hz，H-6’)，6.33(1H，d，J＝2.3Hz，H-3’)，6.26(1H，dd，J＝8.4，2.5Hz，H-5’)，5.92(1H，s，H-6)，5.50(1H，dd，J＝2.8，13.3Hz，H-2)，4.89(1H，t，J＝6.8Hz，H-4”)，4.55(1H，brs)，4.47(1H，brs)，3.1(1H，dd，J＝13.3，17.2Hz，H-3a)，2.62(1H，dd，J＝2.9，17.2Hz，H-3b)，2.4(3H，m)，1.9(2H，m)，1.56(3H，s)，1.52(3H，s)，1.43(3H，s)。
ESIMS(m/z)：423。
Embodiment 3 kuh-seng total flavone extractive HPLC color atlas and quantitative analyses
With the HPLC system kuh-seng total flavone extract (embodiment 1) is carried out quantitative analysis.Instrument: Agilent1100, the setting wavelength is 280nm, and analytical column is Zorbax SB-C18 4.6*150mm, and flow velocity is 1ml/ minute.Moving phase is CH 3CN and H 2O solution.Gradient elution, the gradient situation is: CH 3CN was incremented to 80% from 30% in 25 minutes.In subsequently 5 minutes, CH 3CN is incremented to 100%.Get HPLC collection of illustrative plates shown in the accompanying drawing 3.
Kurarinone, 2 '-methoxyl group kurarinone, all separation and purification in this laboratory of the reference substance of Chinese scholartree flavanone G.Analyze through HPLC, purity is all more than 96%.
The result records and contains kurarinone 40.1% (retention time 16.87 minutes) in the kuh-seng total flavone extract of the present invention (embodiment 1), 2 '-methoxyl group-1 kurarinone 1.8% (retention time 19.99 minutes), Chinese scholartree flavanone G6.2% (retention time 20.65 minutes).
Embodiment 4 detects the restraining effect that kuh-seng total flavone extract and kurarinone are expressed TNF α and IL-1 β in the LPS inductive PBMC cell on cell levels.
Experiment material:
1. cell: peripheral blood lymphocytes
2. be subjected to the reagent thing: kuh-seng total flavone extract (embodiment 1) and kurarinone (091-2)
3. positive control: dexamethasone (DEX)
4. reagent: Ficoll-Paque Plus (Amersham Bioscience); Intracellular toxin (LPS) and dexamethasone (CalBiochem.); TNF α ELISA Kit and IL-1 β ELISA Kit (brilliant U.S. bio-engineering corporation); DMSO (Sigma).
5. method and result:
● fresh blood is antithrombotics with EDTA, and separating periphery blood monocytic cell is suspended in RPMI 1640 substratum that contain 10%FBS.Adding 100 μ l density in 96 orifice plates is 1 * 10 5The new isolated cells of cell/ml, every porocyte adds up to 10 4Individual.Each sample is done 3 holes.
● in cell, add the specimen (final concentration is respectively 10,30 and 100 μ g/ml, and the application of sample amount is 10 μ l) and the positive control (dexamethasone, 10 μ M) of prescribed concentration.Place 37 ℃, contained in the incubator of 5% CO2 insulation 15 minutes.
● adding 10 μ l concentration is the LPS of 100 μ g/ml, places 37 ℃, contains 5% CO 2Incubator in the insulation 16 hours.
● with 1000rpm centrifugal 15 minutes, supernatant is transferred in the 96 new orifice plates, measure TNF α and IL-1 β concentration, or cold storage is avoided multigelation in-20 ℃.
● according to the described method of the producer, utilize TNF α and IL-1 β concentration in the kit measurement cell culture medium.
6. the result calculates:
The typical curve of measuring according to TNFa and IL-1 β detection kit calculate that LPS stimulates and drug treating after the concentration of emiocytosis two cellular inflammation factors to the nutrient solution, the expression inhibiting rate is calculated according to following formula:
Figure A20041003093700131
Experimental result:
The restraining effect that kuh-seng total flavone extract and kurarinone are expressed inflammatory factor
Drug level (μ g/ml) ??TNFa ??(pg/ml) TNFa expression inhibiting rate (%) ??IL-1β ??(pg/ml) IL-1 β expression inhibiting rate (%)
The kuh-seng total flavone extract ??10 ??129.1±10.6 ????34.4±10.1 ??184.9±12.4 ????47.7±10.1
??30 ??50.9±9.8 ????72.9±2.1 ??76.9±10.2 ????76.8±2.1
??100 ??10.4±0.4 ????94.3±2.4 ??19.6±0.4 ????93.9±2.4
Kurarinone ??10 ??92.2±2.7 ????52.5±4.2 ??129.8±8.4 ????62.4±4.2
??30 ??39.5±1.5 ????78.5±4.1 ??80.5±3.7 ????75.0±4.1
??100 ??2.1±0.3 ????98.8±2.1 ??3.1±0.3 ????99.0±0.5
Peripheral blood lymphocytes ??11.0±1.1 ????/ ??5.8±1.0 ????/
LPS ??215.7±36.4 ????/ ??460.8±16.4 ????/
10uM?DEX ??120.9±3.4 ????61.3±1.9 ??275.6±5.3 ????72.9±1.6

Claims (12)

1. a kuh-seng total flavone extract is characterized in that, it comprises following weight ratio composition: kurarinone 20～60%, 2 '-methoxyl group-kurarinone 1～5% and Chinese scholartree flavanone G 1～12%.
2. the kuh-seng total flavone extract of claim 1 is characterized in that, it comprises kurarinone 35～45%, 2 '-methoxyl group-kurarinone 2～4% and Chinese scholartree flavanone G 5～8%.
3. the kuh-seng total flavone extract of claim 2 is characterized in that, it comprises kurarinone 45%, 2 '-methoxyl group-kurarinone 2% and Chinese scholartree flavanone G 6%.
4. the kuh-seng total flavone preparation method of extract of claim 1 is characterized in that, it comprises the steps: kuh-seng through organic solvent extraction, concentrated, and the gained crude extract is dissolved in 5%～50%C 1～C 4Alcohol solution is used organic solvent extraction again, merges organic phase, concentrate product.
5. the method for claim 4, wherein said C 1～C 4Alcohol solution is methyl alcohol, ethanol, propyl alcohol, Virahol or the butanols aqueous solution.
6. the method for claim 4, wherein said C 1～C 4The concentration of alcohol solution is 20～40%.
7. the method for claim 6, wherein said C 1～C 4The concentration of alcohol solution is 30%.
8. pharmaceutical composition, it comprises the kuh-seng total flavone extract of claim 1.
9. the purposes of the kuh-seng total flavone extract of claim 1 in preparation TNF alpha inhibitor.
10. the purposes of claim 9, wherein said TNF alpha inhibitor can be used for treating down one or more in the group illness: rheumatoid arthritis, juvenile rheumatoid arthritis, osteoarthritis, SpA, inflammatory bowel, in heart failure, diabetes, systemic lupus erythematous, scleroderma, sarcoidosis, dermatomyositis, psoriatic, multiple myeloma, myelodysplastic syndrome, acute marrow type leukemia, Parkinson's disease, presenile dementia, dysthymia disorders, acquired immune deficiency syndrome and dementia and syndrome, Sepsis, pyoderma gangraenosum, septicemia, septic shock, behcets disease, graft versus host disease (GVH disease), uveitis, Wegener ' s granuloma, the Xiu Gelianshi xerosis, chronic obstructive pulmonary disease, asthma, acute pancreatitis, periodontopathy, emaciation, central nervous system injury or obesity.
11. the purposes of the kuh-seng total flavone extract of claim 1 in preparation IL-1 beta inhibitor.
12. the purposes of claim 11, wherein said IL-1 beta inhibitor can be used for treating down in the group illness one or more: rheumatoid arthritis, septicemia, periodontopathy, heart failure, dermatomyositis, acute pancreatitis, chronic obstructive pulmonary disease, presenile dementia, osteoarthritis, infectation of bacteria, myelodysplastic syndrome, uveitis, central nervous system injury, asthma, dysthymia disorders or scleroderma.
CNA200410030937XA 2004-04-01 2004-04-01 Kuh-seng flavone extract and preparation and use thereof Pending CN1676520A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CNA200410030937XA CN1676520A (en) 2004-04-01 2004-04-01 Kuh-seng flavone extract and preparation and use thereof
PCT/CN2005/000436 WO2005095375A1 (en) 2004-04-01 2005-04-01 Extract of sophora flavescens flavonoids and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA200410030937XA CN1676520A (en) 2004-04-01 2004-04-01 Kuh-seng flavone extract and preparation and use thereof

Publications (1)

Publication Number Publication Date
CN1676520A true CN1676520A (en) 2005-10-05

Family

ID=35049283

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA200410030937XA Pending CN1676520A (en) 2004-04-01 2004-04-01 Kuh-seng flavone extract and preparation and use thereof

Country Status (2)

Country Link
CN (1) CN1676520A (en)
WO (1) WO2005095375A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100528855C (en) * 2005-12-27 2009-08-19 中国科学院山西煤炭化学研究所 Process for producing kuh-seng total flavone and flavone salt by kuh-seng
CN100528856C (en) * 2005-12-27 2009-08-19 中国科学院山西煤炭化学研究所 Process for producing kuh-seng total flavone and flavone salt
CN102423312A (en) * 2007-02-21 2012-04-25 生物光谱公司 Compositions for improving skin conditions comprising matrine or its oxidized derivatives
CN103598386A (en) * 2013-11-19 2014-02-26 界首市赫赫发食品有限公司 Selenium-supplementation chocolate for children
CN105832718A (en) * 2016-04-26 2016-08-10 宁夏医科大学 Application of sophoraflavanone G in preparation of medicine for preventing and treating diabetic mellitus
CN106309427A (en) * 2016-09-30 2017-01-11 宁夏医科大学 Application of Sophoraflavanone G in preparation of antidepressants and pharmaceutical composition
CN106727495A (en) * 2016-12-29 2017-05-31 云南中医学院 Application of the one class flavanone compound in myocardial preservation medicine is prepared
CN110840928A (en) * 2019-11-29 2020-02-28 广东药科大学 Application of total flavonoids of sophora flavescens in preparing medicine for treating ulcerative colitis
CN115010689A (en) * 2022-07-14 2022-09-06 贵州医科大学 Compound kurarinol A and preparation method and application thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101331784B1 (en) * 2010-09-27 2013-11-21 한국생명공학연구원 Composition for immune enhancement comprising compound in chemical formular one through eight or extract from Sophora flavescens
US11147835B1 (en) 2020-08-20 2021-10-19 Frank Kelly Reilly, III Nutritional supplement

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010084363A (en) * 2000-02-25 2001-09-06 이병훈 Apoptosis-inducing pharmaceutical composition comprising lavandulylflavonoids

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100528856C (en) * 2005-12-27 2009-08-19 中国科学院山西煤炭化学研究所 Process for producing kuh-seng total flavone and flavone salt
CN100528855C (en) * 2005-12-27 2009-08-19 中国科学院山西煤炭化学研究所 Process for producing kuh-seng total flavone and flavone salt by kuh-seng
CN102423312A (en) * 2007-02-21 2012-04-25 生物光谱公司 Compositions for improving skin conditions comprising matrine or its oxidized derivatives
CN103598386A (en) * 2013-11-19 2014-02-26 界首市赫赫发食品有限公司 Selenium-supplementation chocolate for children
CN103598386B (en) * 2013-11-19 2015-01-07 界首市赫赫发食品有限公司 Selenium-supplementation chocolate for children
CN105832718B (en) * 2016-04-26 2018-08-21 宁夏医科大学 Flavones Sophoraflavanone G are preparing the application in preventing diabetes medicament
CN105832718A (en) * 2016-04-26 2016-08-10 宁夏医科大学 Application of sophoraflavanone G in preparation of medicine for preventing and treating diabetic mellitus
CN106309427A (en) * 2016-09-30 2017-01-11 宁夏医科大学 Application of Sophoraflavanone G in preparation of antidepressants and pharmaceutical composition
CN106727495A (en) * 2016-12-29 2017-05-31 云南中医学院 Application of the one class flavanone compound in myocardial preservation medicine is prepared
CN106727495B (en) * 2016-12-29 2019-08-06 云南中医学院 A kind of flavanone compound is preparing the application in myocardial preservation drug
CN110840928A (en) * 2019-11-29 2020-02-28 广东药科大学 Application of total flavonoids of sophora flavescens in preparing medicine for treating ulcerative colitis
CN115010689A (en) * 2022-07-14 2022-09-06 贵州医科大学 Compound kurarinol A and preparation method and application thereof
CN115010689B (en) * 2022-07-14 2023-10-03 贵州医科大学 Compound kurarinol A and preparation method and application thereof

Also Published As

Publication number Publication date
WO2005095375A1 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
CN1676520A (en) Kuh-seng flavone extract and preparation and use thereof
CN1197567C (en) Application of kaempferol and its derivative in preparing medicine for cardiac and cerebral vascular diseases
US20050226943A1 (en) Extract of sophora flavescens flavonoids and uses thereof
CN1919856A (en) Caulis trachelospermi total lignans extractive, extraction method and medicine use of the extractive and active constituent thereof
CN1566124A (en) Cornel extract and use thereof
WO2018081959A1 (en) Extracts of andrographis paniculata, methods for preparation and use thereof
CN1666985A (en) Medical use of andrographolidume and its derivatives and analogs
Yang et al. The Taishan Robinia pseudoacacia polysaccharides enhance immune effects of rabbit haemorrhagic disease virus inactivated vaccines
WO2017092230A1 (en) Biflavone compound and uses thereof for treating cancers and preparing drugs
CN1689628B (en) Medical purpose of creat extract
CN109419787B (en) Application of abietane diterpenoid compound
CN1235581C (en) Method for preparing Sanguis Draxonis flavoniod formulation and its quality controlling method
CN101036646A (en) Quassia wood total alkaloid and the medical function of the monocase alkaloid
CN115998754A (en) Application of saponin derivative in preparing medicament for treating and preventing ulcerative colitis, preparation method and application
TWI435727B (en) Use of modulating secretion of cytokines
CN102106884B (en) Medicinal composition having immunity-regulating function
CN1416881A (en) Medicine composition for treating depression and its prepn
CN105816472A (en) Pharmaceutical composition, medicine and purpose thereof
CN1261143C (en) Separating preparation process of effective part and active component of influenza virus resisting medicine
Oladejo et al. Acute and chronic anti-inflammatory effect of Bryophyllum pinnatum leaf extract on wistar rats
CN108888628B (en) Application of ginsenoside GRh2 in preparing anti-toxoplasma gondii compound preparation and medicine thereof
CN100339353C (en) Preparation method and use of alpine yarrow herb ketoacid
CN100441186C (en) Medical use of artificial lywrine
JP6688585B2 (en) Barrier function improver
CN100528152C (en) 5-hydroxymethyl -2-furol and its derivative analogue medical use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
CI01 Correction of invention patent gazette

Correction item: Inventor

Correct: Zhang Weihan

False: Zhang Weiquan

Number: 40

Volume: 21

CI02 Correction of invention patent application

Correction item: Inventor

Correct: Zhang Weihan

False: Zhang Weiquan

Number: 40

Page: The title page

Volume: 21

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: ZHANG WEIQUAN TO: ZHANG WEIHAN

ERR Gazette correction

Free format text: CORRECT: INVENTOR; FROM: ZHANG WEIQUAN TO: ZHANG WEIHAN

C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication